ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022
March 28, 2023 08:00 ET
|
ProPhase Labs, Inc.
Company highlights key strategic initiatives to grow underlying value in 2023 and beyond Company announces it is in strategic discussions to develop BE-Smart cancer test globally Company to hold a...
ProPhase Labs to Host 2022 Year End Financial Results Conference Call on Tuesday, March 28, 2023 at 11:00 a.m. Eastern Time
March 21, 2023 08:00 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, March 21, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on...
ProPhase Labs Announces New $6 Million Stock Repurchase Program
March 15, 2023 08:00 ET
|
ProPhase Labs, Inc.
Garden City, NY, March 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its Board of...
ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test
March 13, 2023 08:00 ET
|
ProPhase Labs, Inc.
Presentation to be given in Collaboration with the Mayo Clinic at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting Company’s findings to be presented in a headline Poster...
ProPhase Labs’ Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test
March 07, 2023 08:00 ET
|
ProPhase Labs, Inc.
Company Provides Update on Significant Progress at Nebula Genomics Subsidiary Garden City, NY, March 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented...
ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
March 01, 2023 08:00 ET
|
ProPhase Labs, Inc.
Company Outlines BE-Smart Test Roadmap for Commercialization in the U.S. Company in Early Stages of Exploring Development for Commercialization in Other Countries Garden City, NY, March 01,...
ProPhase Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)
February 22, 2023 08:00 ET
|
ProPhase Labs, Inc.
Goal to launch commercially in Q4 2023 Garden City, NY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics...
ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science
February 16, 2023 08:00 ET
|
ProPhase Labs, Inc.
Garden City, NY, Feb. 16, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its flagship...
ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand
February 15, 2023 08:00 ET
|
ProPhase Labs, Inc.
Garden City, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today provided a...
ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy
February 06, 2023 08:00 ET
|
ProPhase Labs, Inc.
Garden City, NY, Feb. 06, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today provided an...